In this quarter's report, we cover catalysts from 24 drugs, devices and diagnostics. We have also included a list of Large Impact catalysts in the drug and device/diagnostic areas through Q3 2015 from our sister product, CatalystTracker. In addition, each drug’s likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

Our Q2 Outlook Report highlighted several high-impact catalysts. The results of these catalysts can be found on Page 5 of this report. BioMedTracker Likelihood of Approval (LOA) opinions successfully predicted 100% of catalyst outcomes that occurred in Q2 2015.

For the full report, please download the PDF version at the top of this page. Additionally, the catalyst calendars are provided in Excel by downloading the supplemental material above.

For our disclosures, please read the BioMedTracker Research Standards.